Si-bone reaffirms 2026 revenue outlook as Onyx launch targets $5B annual market opportunity

• “We delivered a solid third quarter with accelerating procedure demand, broader physician adoption and improving financial performance,” said (CEO & Director Laura Francis), highlighting “disciplined execution of our multiyear strategy to expand our differentiated platform into new clinical applications.”

• (CEO & Director Francis) tied the quarter’s performance to volume and adoption, stating: “Worldwide revenue grew approximately 15% to $55.7 million. U.S. revenue increased approximately 14% to $52.8 million. U.S. procedure volume increased approximately 20%, supported by 16% growth in active physicians.”

• On product expansion beyond the pelvis, (CEO & Director Francis) said: “With the recent launch of iFuse Granite Onyx, we’re now taking that proven expertise in developing anatomy-specific solutions beyond the pelvis,” adding, “Onyx received FDA 510(k) clearance in September.” She characterized Onyx as “one of the most significant product launches in our history,” and said, “The addition of Onyx increases our estimated total addressable market to over 650,000 procedures, representing an annual total market opportunity of approximately $5 billion.”

• On reimbursement, (CEO & Director Francis) said: “New DRGs for multilevel spinal fusion procedures that incorporate pelvic fixation with Granite took effect October 1,” and added: “Depending on patient diagnosis and severity, the increase in the average hospital payment could be up to $50,000 per qualifying procedure.”

• (COO & CFO Anshul Maheshwari) emphasized mix dynamics alongside growth: “U.S. revenue increased 13.9% to $52.8 million, driven by 19.5% procedure volume growth, partially offset by lower average selling price,” with ASP impacted by “procedure mix” and “site of care mix as our INTRA platform adoption increased in faster-growing ASC and in-office settings, which typically carry lower ASP.”

Outlook

• (COO & CFO Maheshwari) reaffirmed full-year targets: “We are reaffirming our 2026 worldwide revenue of $231 million to $233 million as well as our gross margin expectations at 79%.”

• (COO & CFO Maheshwari) updated expense expectations: “Based on the year-to-date performance, we now expect our operating expenses to grow 10.5% versus our prior expectation of 12%,” while also noting “growth-oriented investments related to Onyx launch and ongoing R&D projects.”

• (COO & CFO Maheshwari) described implied Q4 acceleration: “The midpoint of our annual worldwide revenue guidance implies over 20% year-over-year revenue growth in the fourth quarter,” and said Q4 is “anchored by the strengthening and broad-based procedure demand, a growing base of active physicians, an expanded commercial footprint and modest contribution from new products.”

Financial Results

• (COO & CFO Maheshwari) detailed profitability and losses: “Gross profit increased 13.7% to $44.2 million. Gross margin was 79.3%, continuing to track ahead of guidance,” and “Net loss narrowed to $3.6 million or $0.08 per diluted share compared to a net loss of $4.6 million or $0.11 per diluted share.”

• (COO & CFO Maheshwari) quantified operating leverage and EBITDA: “Operating expenses increased 9.7%, well below revenue growth of 14.5%,” and “Adjusted EBITDA increased 32.4% to $3 million, representing an adjusted EBITDA margin of 5.5%.”

• (COO & CFO Maheshwari) highlighted liquidity and cash generation: “We ended the quarter with $146.3 million in cash and equivalents,” and “Year-to-date, we generated approximately $4.4 million in operating cash flow compared with $2.4 million used in the prior year period.”

Q&A

• Patrick Wood, UBS: Asked for “extra color” on Onyx feedback and how much Onyx supports momentum into next year; (CEO & Director Francis) said early alpha-launch checkpoints were all positive: “the answer is yes to that question,” including use “when they don’t go to the pelvis,” and interest from “nonusers of Granite,” concluding, “we have actually quite a bit of inbound demand already for Onyx… and then we expect the full launch in January.”

• Matthew O’Brien, Piper Sandler: Pressed on how quickly SI-BONE can reach its “roughly” 1,800 active docs and training needs; (CEO & Director Francis) said rollout is tied to capacity, noting, “every single week, we’re pushing out more trays into the field,” and that training is “very straightforward… the adoption and the road to training these surgeons is a very quick one.”

• Matthew O’Brien, Piper Sandler: Questioned the “strongest foundation for growth acceleration” language versus Street expectations; (COO & CFO Maheshwari) listed “top 6” tailwinds including interventional expansion, potential reimbursement changes, Smith+Nephew momentum, DRGs, Onyx ramp, and potential NTAP, but said, “we want to get a few more months behind us… before we talk about 2027.”

• Richard Newitter, Truist: Asked about profitability ramp and ASP step-down; (COO & CFO Maheshwari) said operating leverage remains a target, “on the low end, it’s 1.25x revenue growth to OpEx growth,” and on ASP added, “you should see an improvement in ASP in the fourth quarter,” citing Onyx/Granite dynamics despite interventional mix.

• Gracia Mahoney, BofA: Asked if DRGs benefit Onyx and NTAP timing; (CEO & Director Francis) said DRGs “went into place on October 1, 2026,” and for Onyx, “We have already applied for an NTAP with CMS… if approved, the NTAP would take effect on October 1, 2027,” with “April” as an earlier update point.

• Mathew Blackman, TD Cowen: Asked about need for outcomes data to drive Onyx adoption; (CEO & Director Francis) said SI-BONE will “launch a prospective multicenter clinical study,” and added surgeons often want “6 to 12 months” of early experience, while studies are typically run “at least 2 years, if not 5 years.”

Sentiment Analysis

• Analyst sentiment was slightly positive and detail-seeking, with repeated Onyx focus (launch execution, attachment rate, data needs) and reimbursement mechanics; questions framed uncertainty around adoption and economics, including requests for “commercial clinical and economic outcomes data” (Mathew Blackman, TD Cowen).

• Management sentiment was positive and confident in catalysts, repeatedly pointing to early demand and rollout cadence; (CEO & Director Francis) said, “we’re really excited by what we’re seeing,” and (COO & CFO Maheshwari) said, “Early indications from these catalysts in October reinforce our confidence in a strong finish to 2026.”

• Versus Q2’s more measured framing around timing, Q3 language was more emphatic on launch significance and Q4 acceleration; in Q2, (COO & CFO Maheshwari) said SI-BONE would “maintain[] a measured approach on the impact of these catalysts,” while in Q3 (CEO & Director Francis) said, “Together, these developments mark a defining moment for SI-BONE.”

Quarter-over-Quarter Comparison

• In Q2, (CEO & Director Francis) positioned the third breakthrough device as “submitted” with launch “in the fourth quarter, perhaps as early as October”; in Q3, she stated, “Onyx received FDA 510(k) clearance in September,” and added, “We initiated the alpha launch of Onyx in October.”

• Guidance stance shifted from Q2’s raised low end to Q3’s reaffirmation and tighter OpEx view; Q2 (COO & CFO Maheshwari) said, “We are raising the low end of our 2026 worldwide revenue guidance,” while Q3 he said, “We are reaffirming our 2026 worldwide revenue of $231 million to $233 million,” and “now expect our operating expenses to grow 10.5% versus our prior expectation of 12%.”

• Q3’s procedure growth narrative intensified; Q2 (CEO & Director Francis) said, “Sequentially, U.S. procedure volume increased approximately 9%,” while Q3 she said, “U.S. procedure volume increased approximately 20%.”

• Analyst focus stayed consistent on new-product ramp and reimbursement, but Q3 questions concentrated more heavily on Onyx commercialization (attachment, halo effect, training, data), reflecting the move from filing/anticipated clearance (Q2) to alpha launch (Q3).

Risks and Concerns

• (COO & CFO Maheshwari) flagged mix-driven ASP pressure: “procedure volume growth… partially offset by lower average selling price,” with ASP impacted by “procedure mix” and “site of care mix.”

• (COO & CFO Maheshwari) outlined expected gross margin headwinds into 2027: “we do anticipate some modest gross margin pressure… from the higher noncash depreciation expenses associated with the additional Onyx surgical capacity,” while saying long-term gross margin expectations remain “in sort of that 78% area as you go beyond 2027.”

• (CEO & Director Francis) acknowledged adoption friction tied to evidence: “there are going to be others that are going to wait,” and said some surgeons typically want “6 to 12 months” of results to review.

Final Takeaway

Management framed Q3 as a transition quarter where accelerating procedure demand and expanding call points were paired with a major platform expansion: Onyx moved from a planned late-year launch to FDA clearance and an October alpha launch, while new Granite DRGs took effect October 1 with potential hospital payment increases “up to $50,000 per qualifying procedure.” Leadership reaffirmed 2026 revenue guidance of $231 million to $233 million and 79% gross margin expectations, reduced its operating expense growth outlook to 10.5%, and positioned Q4 as a seasonally strong quarter with implied “over 20%” year-over-year growth at the guidance midpoint, supported by interventional momentum, trauma collaboration, DRG tailwinds, and modest initial Onyx contribution.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.